Supernus Pharmaceuticals Inc (SUPN) — Cash Flow Quality Index
Supernus Pharmaceuticals Inc (SUPN) has a Cash Flow Quality Index of 2.60x as of June 2025. Operating cash flow of $58.53 Million exceeds net income of $22.50 Million, indicating high earnings quality where cash backs reported profits. Explore long-term investment intensity of Supernus Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Supernus Pharmaceuticals Inc Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Supernus Pharmaceuticals Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check SUPN intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Supernus Pharmaceuticals Inc (2009–2024)
Year-by-year earnings quality comparison for Supernus Pharmaceuticals Inc. For live market cap and the full company financial profile, see Supernus Pharmaceuticals Inc market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 2.33x | $171.95 Million | $73.86 Million | ▼ -97.2% |
| 2023 | 84.41x | $111.08 Million | $1.32 Million | ▲ +4286.6% |
| 2022 | 1.92x | $116.83 Million | $60.71 Million | ▼ -19.1% |
| 2021 | 2.38x | $127.13 Million | $53.42 Million | ▲ +118.3% |
| 2020 | 1.09x | $138.40 Million | $126.95 Million | ▼ -13.9% |
| 2019 | 1.27x | $143.13 Million | $113.06 Million | ▲ +8.9% |
| 2018 | 1.16x | $128.99 Million | $110.99 Million | ▼ -41.9% |
| 2017 | 2.00x | $114.64 Million | $57.28 Million | ▲ +173.2% |
| 2016 | 0.73x | $66.81 Million | $91.22 Million | ▼ -68.0% |
| 2015 | 2.29x | $32.12 Million | $14.02 Million | ▲ +488.9% |
| 2014 | 0.39x | $7.73 Million | $19.87 Million | ▼ -38.9% |
| 2009 | 0.64x | $2.63 Million | $4.14 Million | — |